Rejuvenate Bio banks $10M to advance gene therapy for aging in humans and dogs
What if we could tackle multiple age-related ailments such as heart failure and kidney failure with a single injection, instead of piling on many different treatments? That’s the goal for Rejuvenate Bio, a Harvard startup working on a combination gene therapy to reverse aging in people—and in dogs.
The company raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 diabetes and obesity.
“We are fortunate to double-dip on our data—often, data generated in dogs not only serves as a step forward for animal health, but also as preclinical data for human health products,” said Rejuvenate Bio CEO Dan Oliver, who co-founded the company alongside renowned geneticist George Church, Ph.D., and Noah Davidsohn, Ph.D., a former postdoctoral fellow in Church’s lab at Harvard and the company’s chief scientific officer.
“A key experiment outstanding for us is an FDA safety trial if viewed from the animal health lens, which will also serve as a pre-IND toxicity study for human clinical trials,” Oliver said.
